Left Main PCI Technique Could Change DAPT Duration

Up to 20% of patients undergoing left main PCI require a 2-stent technique, and this number should most likely grow after the DKCRUSH-V outcomes. However, this study contradicts the DKCRUSH-V and brings us back to “the simpler the better”, since patients undergoing 1 stent left main PCI presented less revascularization and less target vessel failure than patients undergoing 2 stent PCI. Even more, it suggests extending DAPT when using a 2-stent technique.

La ATC es una alternativa válida en el TCIThe aim of this study was to assess the impact of DAPT duration according to the chosen technique to treat left main bifurcations.

 

Researchers analyzed 5 multicenter registries looking into a combination of target vessel failure and thrombotic events, in addition to differences in the individual components. They carried out a subgroup analyzis according to DAPT duration.


Read also: DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery.


Of the 13172 registry patients undergoing PCI with new generation stents, 700 received left main bifurcation PCI (567 with 1 stent and 133 with 2 stents).

 

Target vessel failure and revascularization rates were higher in the 2-stent group (most lesions were more anatomically complex).

 

Thrombotic event risk was comparable between both strategies, though the subgroup analyzis showed the 2-stent group had a significantly higher risk when receiving DAPT for 1 year, while the risk was similar when DAPT went on for longer.  


Read also: EXCEL-QOL Substudy: Similar Quality of Life both with CABG and Left Main PCI.


This study shows that complex PCI might help redefine DAPT duration.

 

Original title: Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention.

Reference: Tae-Min Rhee et al. J Am Coll Cardiol Intv 2018;11:2453–63.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...

Dual-Prep Registry: Atherectomy and IVL for Severe Coronary Calcification

Severe coronary calcification remains one of the most challenging scenarios in percutaneous coronary intervention (PCI). Although rotational or orbital atherectomy and intravascular lithotripsy (IVL)...

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...